Nationwide Fund Advisors’s Navidea Biopharmaceuticals Inc. NAVB Stock Holding History

Nationwide Fund Advisors’s Portfolio NAVB Stock Details NAVB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	–	Sell	-6,873	Closed	-$130K	–	3339
2016 Q1	$130K	Buy	6,873 +1,995	+41%	+$38.4K	﹤0.01%	2719
2015 Q4	$130K	Buy	4,878 +112	+2%	+$3.89K	﹤0.01%	2747
2015 Q3	$217K	Hold	4,766	–	–	﹤0.01%	2524
2015 Q2	$153K	Sell	4,766 -774	-14%	-$22.5K	﹤0.01%	2855
2015 Q1	$176K	Sell	5,540 -285	-5%	-$9.64K	﹤0.01%	2758
2014 Q4	$220K	Hold	5,825	–	–	﹤0.01%	2583
2014 Q3	$154K	Buy	5,825 +83	+1%	+$2.2K	﹤0.01%	2817
2014 Q2	$170K	Buy	5,742 +1,062	+23%	+$34.3K	﹤0.01%	2828
2014 Q1	$173K	Hold	4,680	–	–	﹤0.01%	2546
2013 Q4	$194K	Sell	4,680 -67	-1%	-$2.62K	﹤0.01%	2704
2013 Q3	$252K	Buy	4,747 +500	+12%	+$29.1K	﹤0.01%	2551
2013 Q2	$227K	Buy	+4,247	New	+$212K	﹤0.01%	2432

Other funds holding NAVB

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

HIIFS

Harel Insurance Investments & Financial Services Ramat Gan, Israel $14.7B AUM 47% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Paloma Partners Greenwich, Connecticut $510M AUM 286.05% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Nationwide Fund Advisors's NAVB Position: Q2 2016 in Review

Nationwide Fund Advisors sold out of Navidea Biopharmaceuticals Inc. (NAVB) in Q2 2016, closing a stake of 6,873 shares — an estimated $130K sold.

Nationwide Fund Advisors first reported a position in NAVB in Q2 2013 and held it in 12 quarters. The position peaked at $252K in Q3 2013. 63 funds tracked by Wall St. Rank hold NAVB as of Q2 2016.

Nationwide Fund Advisors reported no remaining Navidea Biopharmaceuticals Inc. position as of Q2 2016 after selling out during the quarter.
Nationwide Fund Advisors sold 6,873 Navidea Biopharmaceuticals Inc. shares in Q2 2016, an estimated $130K.
Nationwide Fund Advisors first reported a position in Navidea Biopharmaceuticals Inc. in Q2 2013 and held it in 12 quarters.
Nationwide Fund Advisors's Navidea Biopharmaceuticals Inc. position peaked at $252K in Q3 2013.
63 funds tracked by Wall St. Rank held Navidea Biopharmaceuticals Inc. as of Q2 2016.

Based on Nationwide Fund Advisors's 13F filing for Q2 2016, filed 9 Aug 2016.